Genmab A/S (GMAB) |
|
38.87 0.19 (0.49%)
|
01-27 16:00 |
|
Open: |
38.6 |
Pre. Close: |
38.68 |
|
High:
|
39.04 |
Low:
|
38.52 |
|
Volume:
|
578,372 |
Market Cap:
|
25,639(M) |
|
|
|
Technical analysis |
as of: 2023-01-27 4:44:55 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 48.66 One year: 50.99 |
| Support: |
Support1: 38.43 Support2: 31.98 |
| Resistance: |
Resistance1: 41.66 Resistance2: 43.65 |
| Pivot: |
40.25  |
| Moving Average: |
MA(5): 39.04 MA(20): 40.82
MA(100): 39.86 MA(250): 36.12 |
| MACD: |
MACD(12,26): -1.2 Signal(9): -1 |
| Stochastic oscillator: |
%K(14,3): 6.5 %D(3): 6.1 |
| RSI: |
RSI(14): 33.7 |
| 52-week: |
High: 47.5 Low: 26.19 |
| Average Vol(K): |
3-Month: 673 (K) 10-Days: 589 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ GMAB ] has closed above bottom band by 26.2%. Bollinger Bands are 11.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
39.13 - 39.39 |
39.39 - 39.62 |
|
Low:
|
37.87 - 38.21 |
38.21 - 38.51 |
|
Close:
|
38.36 - 38.88 |
38.88 - 39.35 |
|
Company Description |
|
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark. |
Headline News |
Fri, 27 Jan 2023
Babcock & Wilcox Awarded $65 Million Providing Services for UK ... - Environment + Energy Leader
Tue, 24 Jan 2023
Genmab A/S - ADR (GMAB) is lower by 1.63% Tuesday In Premarket Trading - InvestorsObserver
Mon, 23 Jan 2023
AbCellera Biologics Clears Key Benchmark, Hitting 80-Plus RS Rating - Investor's Business Daily
Mon, 23 Jan 2023
GILD or GMAB: Which Is the Better Value Stock Right Now? - Zacks Investment Research
Mon, 23 Jan 2023
Stocks Showing Improving Market Leadership: ACADIA ... - Investor's Business Daily
Fri, 20 Jan 2023
Artisan Mid Cap Fund Exited Its Position in Genmab A/S (GMAB) For Better Opportunities - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Outperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
660 (M) |
| Shares Float |
645 (M) |
|
% Held by Insiders
|
0 (%) |
|
% Held by Institutions
|
6.9 (%) |
|
Shares Short
|
3,210 (K) |
|
Shares Short P.Month
|
3,440 (K) |
Stock Financials |
|
EPS
|
1.2 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
40.86 |
|
Profit Margin (%)
|
47.1 |
|
Operating Margin (%)
|
37.5 |
|
Return on Assets (ttm)
|
10.2 |
|
Return on Equity (ttm)
|
23.5 |
|
Qtrly Rev. Growth
|
76.9 |
|
Gross Profit (p.s.)
|
12.85 |
|
Sales Per Share
|
18.17 |
|
EBITDA (p.s.)
|
7.21 |
|
Qtrly Earnings Growth
|
190.8 |
|
Operating Cash Flow
|
3,760 (M) |
|
Levered Free Cash Flow
|
2,440 (M) |
Stock Valuations |
|
PE Ratio
|
32.39 |
|
PEG Ratio
|
0.1 |
|
Price to Book value
|
0.95 |
|
Price to Sales
|
2.13 |
|
Price to Cash Flow
|
6.81 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
